Our current partners:
ALK is a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Chiesi is an international pharmaceutical company, dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases.
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. Napp believe in excellence and delivering on our promises to the NHS, patients, our business partners and each other. Napp strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.
Novartis champions scientific research and innovation to help improve healthcare and reimagine medicine, both in the UK and around the world.
Orion is a Finnish-born, innovative European R&D-based pharmaceuticals and diagnostics company with an emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients as well as diagnostic tests. Orion carries out extensive research with a goal of introducing new treatments into global markets. The core therapy areas in Orion’s product and research strategy are the central nervous system, oncology, critical care and respiratory medicines.
Our partnership with Vax provides us with a platform to communicate key health advice messages directly to people with asthma. The partnership will ensure that people who purchase Vax air purifiers are given advice and support on steps they can take to reduce the impact of harmful triggers and prevent life-threatening asthma attacks.
Vectura is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With an extensive range of device and formulation technologies, integrated capabilities and collaborations, Vectura are a leader in the development of inhalation products, increasing their ability to help patients suffering from respiratory diseases.
Are you interested in partnering with Asthma UK?
Call Brigitte West on 0207 786 5044 or email firstname.lastname@example.org for more information on how your organisation can get involved with Asthma UK.